Inventor
Jason D. Speake
Inventor
Winston-Salem, NC, US
Overview
Patents· 28 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations27%
A61KPreparations for medical, dental or toiletry purposes20%
A01NPreservation of bodies of humans or animals or plants or parts thereof10%
C07CAcyclic or carbocyclic compounds7%
Y02ATechnologies for adaptation to climate change2%
C04BLime, magnesia1%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
PatentTitleYear
10,961,261Oxaborole analogs and uses thereof202110,807,992Single enantiomer antiparasitic compounds202010,772,331Antiparasitic compounds202010,744,136Sulfonamide derivatives as JAK inhibitors202010,716,770Nicotinic receptor non-competitive antagonists202010,570,144Substituted ureas as prostaglandin EP4 receptor antagonists202010,556,909Synthetic process and intermediates202010,342,234Antiparasitic compounds201910,258,582Nicotinic receptor non-competitive antagonists201910,239,885Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-a]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist201910,092,001Antiparasitic compounds20189,883,674'Antiparasitic compounds'20189,686,991'Antiparasitic compounds'20179,643,963'Antiparasitic compounds'20179,532,974'Nicotinic receptor non-competitive antagonists'20179,420,793'Antiparasitic compounds'20169,173,876'Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide'20158,901,151'Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide'20148,822,518'Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction'20148,809,397'Nicotinic receptor non-competitive antagonists'20148,633,175'Compounds as antagonists or inverse agonists at opioid receptors'20148,476,296'Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide'20137,939,528'Heterocycle compounds'20117,625,909'Substituted quinazolinone compounds'20097,442,693'Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors'20087,368,453'Quinazolinone compounds with reduced bioaccumulation'20087,285,557'Pyrimidinones as melanin concentrating hormone receptor 1'20076,884,801'Imidazoline derivatives as alpha-1A adrenoceptor ligands'2005Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2005–2008Patents assigned to SMITHKLINE BEECHAM CORP (2)· patent assignee history
2005–2021Based in Durham, NC, US· patent location history
2008–2014Based in Cary, NC, US· patent location history
2011–2014Patents assigned to GLAXOSMITHKLINE LLC (3)· patent assignee history
2013–2017Patents assigned to TARGACEPT INC (5)· patent assignee history
2013–2020Based in Winston-Salem, NC, US· patent location history
2014Based in Research Triangle Park, NC, US· patent location history
2017–2020Patents assigned to AVISTA PHARMA SOLUTIONS INC (11)· patent assignee history
2019–2020Patents assigned to CATALYST BIOSCIENCES INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| AVISTA PHARMA SOLUTIONS INC | 11 | 2017–2020 |
| TARGACEPT INC | 5 | 2013–2017 |
| GLAXOSMITHKLINE LLC | 3 | 2011–2014 |
| CATALYST BIOSCIENCES INC | 2 | 2019–2020 |
| SMITHKLINE BEECHAM CORP | 2 | 2005–2008 |
Locations
| Location | Patents | Span |
|---|---|---|
| Winston-Salem, NC, US | 19 | 2013–2020 |
| Durham, NC, US | 5 | 2005–2021 |
| Cary, NC, US | 3 | 2008–2014 |
| Research Triangle Park, NC, US | 1 | 2014 |